Payment overview · 2025
General Payments
$6,324.44
331 reported records · 33 companies
Healthcare provider profile · identity verified
Ann Celeste Mapas Dimaya, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · EAST HAVEN, CT · NPI 1295994721
Verified facts
What the public records show
CMS Open Payments records show Ann Celeste Mapas Dimaya, M.D. received $6,324.44 in general payments during 2025 across 331 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 15.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 55 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abilify Maintena, Caplyta, Eliquis, Farxiga, Gemtesa, Jardiance, Mounjaro, Qulipta, Rexulti, Trelegy Ellipta, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trelegy Ellipta by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Caplyta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Abilify Maintena by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $998.28 | 15.8% | 49 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $993.24 | 15.7% | 51 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $489.32 | 7.7% | 20 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $433.48 | 6.8% | 19 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $425.62 | 6.7% | 23 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $399.34 | 6.3% | 17 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $305.27 | 4.8% | 15 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $227.99 | 3.6% | 11 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $223.24 | 3.5% | 16 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $205.97 | 3.3% | 14 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $197.91 | 3.1% | 24 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $190.37 | 3.0% | 12 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $162.52 | 2.6% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $122.04 | 1.9% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $119.41 | 1.9% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $100.58 | 1.6% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $95.63 | 1.5% | 5 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $91.23 | 1.4% | 4 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $80.47 | 1.3% | 5 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $80.15 | 1.3% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $53.96 | 0.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.14 | 0.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $45.59 | 0.7% | 2 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $42.35 | 0.7% | 2 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $35.15 | 0.6% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $32.89 | 0.5% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $23.19 | 0.4% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $22.99 | 0.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.70 | 0.3% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $17.28 | 0.3% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $14.39 | 0.2% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.87 | 0.2% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $11.88 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $6,324.44 | 331 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $998.28 | 49 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $728.47 | 37 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $648.62 | 29 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $425.62 | 23 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $299.01 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $264.77 | 14 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $213.79 | 12 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $211.69 | 10 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $197.91 | 24 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $167.47 | 6 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $162.52 | 12 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $157.29 | 6 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $153.47 | 5 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $137.76 | 10 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $124.59 | 8 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $119.41 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $118.55 | 7 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $104.69 | 9 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $100.58 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $96.38 | 6 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $95.63 | 5 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $91.23 | 4 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $91.23 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $85.35 | 4 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $80.15 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $72.30 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $72.30 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $62.30 | 3 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Optinose US, Inc., Paratek Pharmaceuticals, Inc. | $56.22 | 3 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $55.42 | 4 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $53.96 | 2 | 2025 |
Source payment records
|
|||||
| AZMIRO Normalized: azmiro |
Drug | Azurity Pharmaceuticals, Inc. | $48.78 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $48.14 | 2 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $35.15 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $32.89 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $26.91 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $25.32 | 1 | 2025 |
Source payment records
|
|||||
| LAGEVRIO Normalized: lagevrio |
Drug | Merck Sharp & Dohme LLC | $24.53 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $23.38 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $23.19 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $22.99 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $21.06 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $21.06 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| KATERZIA Normalized: katerzia |
Drug | Azurity Pharmaceuticals, Inc. | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $13.87 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $11.88 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $5.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABILIFY MAINTENA abilify maintena |
2025 | Abilify Maintena | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 39 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 43 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 80 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 64 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
64 | 17 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
80 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 186 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 120 | 26 |
| Amlodipine Besylate | Amlodipine Besylate | 114 | 32 |
| Gabapentin | Gabapentin | 110 | 21 |
| Levothyroxine Sodium | Levothyroxine Sodium | 107 | 21 |
| Alprazolam | Alprazolam | 103 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 98 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 95 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 90 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 89 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 87 | 24 |
| Mounjaro | Tirzepatide | 80 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 70 | 18 |
| Furosemide | Furosemide | 69 | 13 |
| Lisinopril | Lisinopril | 67 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 64 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 64 | 17 |
| Famotidine | Famotidine | 60 | 14 |
| Prednisone | Prednisone | 60 | 38 |
| Sertraline Hcl | Sertraline Hcl | 59 | 12 |
| Metformin Hcl | Metformin Hcl | 58 | 14 |
| Vascepa | Icosapent Ethyl | 57 | 13 |
| Losartan Potassium | Losartan Potassium | 56 | 15 |
| Montelukast Sodium | Montelukast Sodium | 56 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | 12 |
| Trazodone Hcl | Trazodone Hcl | 54 | 13 |
| Ozempic | Semaglutide | 45 | suppressed |
| Azithromycin | Azithromycin | 44 | 31 |
| Clonazepam | Clonazepam | 44 | 11 |
| Diazepam | Diazepam | 44 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 43 | 13 |
| Ammonium Lactate | Ammonium Lactate | 42 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 13 |
| Ezetimibe | Ezetimibe | 40 | suppressed |
| Pregabalin | Pregabalin | 40 | 11 |
| Topiramate | Topiramate | 40 | suppressed |
| Caplyta | Lumateperone Tosylate | 39 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | suppressed |
| Gemtesa | Vibegron | 39 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 11 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 39 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | 11 |
| Mirtazapine | Mirtazapine | 35 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 33 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | suppressed |
| Vraylar | Cariprazine Hcl | 31 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | 18 |
| Clotrimazole | Clotrimazole | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Simvastatin | Simvastatin | 29 | suppressed |
| Carvedilol | Carvedilol | 28 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Omeprazole | Omeprazole | 26 | suppressed |
| Rexulti | Brexpiprazole | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 16 |
| Trintellix | Vortioxetine Hydrobromide | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Eliquis | Apixaban | 23 | suppressed |
| Nystatin | Nystatin | 23 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 16 |
| Movantik | Naloxegol Oxalate | 20 | suppressed |
| Pentoxifylline | Pentoxifylline | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Buprenorphine | Buprenorphine | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 12 |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Acarbose | Acarbose | 14 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 14 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Abilify Maintena | Aripiprazole | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Qulipta | Atogepant | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $6,324.44 · 331 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABILIFY ASIMTUFII, ABILIFY MAINTENA, AIRSUPRA, ARISTADA, AUSTEDO XR, AZMIRO, Auvelity, Azstarys, BREZTRI, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, FANAPT, FARXIGA, Fibroscan, GARDASIL 9, GEMTESA, GLYCATE, HORIZANT, IBSRELA, INGREZZA, JARDIANCE, KATERZIA, KRYSTEXXA, LAGEVRIO, LYBALVI, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, PAXLOVID, PURIFIED CORTROPHIN GEL, QULIPTA, RELISTOR, RELTONE 200 MG, RELTONE 400 MG, REPATHA, REXULTI, Sunosi, Symbravo, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VRAYLAR, VYEPTI, Veozah, Wegovy, XHANCE, XIFAXAN, XYOSTED, YUPELRI, ZEPBOUND, ZORYVE, ZTLido | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abilify Maintena play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error